Sugi Predict

Sugi Predict / Compounds / SCHEMBL25752494

SCHEMBL25752494

SCHEMBL25752494

COc1nccc2c1c(NC(=O)OC(C)(C)C)cn2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.41
▸ ABL1 P00519 4/20 0.38
▸ PIK3CD O00329 2/20 0.38
▸ EGFR P00533 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ PIK3CA P42336 2/20 0.38
▸ PIK3CG P48736 2/20 0.38
▸ PRKDC P78527 2/20 0.38
▸ SRC P12931 2/20 0.38
▸ HCK P08631 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ EPHB4 P54760 1/20 0.38
▸ CYP17A1 P05093 4/20 0.38
▸ BACE1 P56817 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ METAP1 P53582 1/20 0.37
▸ DYRK1A Q13627 2/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27199281 0.84 BRD4 (0.34) KDRIRAK4BRD4
SCHEMBL25670291 0.78 CNR2 (0.39) ATRABL1PIK3CDEGFRKDR
SCHEMBL38662365 0.76 ATR (0.47) ATRABL1PIK3CDEGFRKDR
SCHEMBL30937713 0.75 ATR (0.46) ATRABL1PIK3CDEGFRKDR
SCHEMBL5779641 0.75 ATR (0.46) ATRABL1PIK3CDEGFRKDR
SCHEMBL30283184 0.74 METAP1 (0.54) ATRCYP17A1METAP1BRD9NAMPT
SCHEMBL1723318 0.74 METAP1 (0.54) ATRCYP17A1METAP1BRD9NAMPT
SCHEMBL25752496 0.73 CNR2 (0.38) CNR2
SCHEMBL25750429 0.73 ELANE (0.38) ATRABL1PIK3CDEGFRKDR
SCHEMBL25670769 0.73 CNR2 (0.42) CYP17A1CNR2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ATR 189/4885ABL1 6/4885PIK3CD 732/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ATR 189/4885ABL1 6/4885PIK3CD 732/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 ATR 189/4885ABL1 6/4885PIK3CD 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.